Eupraxia Pharmaceuticals is trading 10.63% up at $9.19; the clearest catalyst is its September 30 RESOLVE trial report. - In Phase 1b/2a, 9 of 14 patients (64%) remained in clinical remission 52 weeks after one EP-104GI administration; 2 of 3 in the highest-dose cohort remained in remission. - The report does not quantify or attribute a share-price reaction. - The Phase 2b trial is recruiting, with interim data expected in December 2026.